Richard Drury
- Vigil Neuroscience (NASDAQ:VIGL) announced on Wednesday that a mid-stage trial for its lead candidate, iluzanebart, didn’t succeed in patients with a rare neurological disease called adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
- The Watertown, Massachusetts-based biotech, which recently agreed to